Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome

Tocilizumab (TCZ) is the first FDA- approved treatment for systemic juvenile idiopathic arthritis (sJIA). We report 3 cases of cytopenias in children with sJIA treated with TCZ. Two of the children who developed significant cytopenias shortly after initiation of TCZ had a history of macrophage activ...

Descripción completa

Detalles Bibliográficos
Autores principales: Kessler, Elizabeth A, Vora, Sheetal S, Verbsky, James W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3511797/
https://www.ncbi.nlm.nih.gov/pubmed/22931129
http://dx.doi.org/10.1186/1546-0096-10-30

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3511797/
https://www.ncbi.nlm.nih.gov/pubmed/22931129
http://dx.doi.org/10.1186/1546-0096-10-30

Ejemplares similares